Database lists somatic EGFR mutations

The denosumab-bmwo products Stoboclo and Osenvelt have been approved as interchangeable with the denosumab products Prolia and Xgeva, respectively.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Definitive concurrent chemoradiation followed by consolidation durvalumab in the absence of progression remains the standard of care for stage III NSCLC.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

A unique cisplatin-containing intratumoral formulation achieved a median OS of 18.7 months in patients who were dosed at 40% or more of their TTB.

Researchers have determined that donor age has a stronger, nonlinear impact on OS vs donor type in allogeneic HCT using posttransplant cyclophosphamide for GVHD prophylaxis, with donor type becoming increasingly relevant in older donors.